Industry leading survey of Venture Capital (VC) life sciences investors of funds managing c.$300bn
VCs favouring new investments over existing portfolio and have money to deploy M&A expected to be strong Top investor requirements – Team, Science and Differentiation London, UK, 11 December 2024: Optimum Strategic Communications (‘Optimum’), the international strategic life sciences communications firm, today announces the results of its Optimum European Life Sciences Investor Survey 2025: […]